These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 3271644)
21. Liquid chromatographic analysis in mouse, dog and human plasma; stability, absorption, metabolism and pharmacokinetics of the anti-HIV agent 2-chloro-5-(2-methyl-5,6-dihydro-1,4-oxathiin-3-yl carboxamido) isopropylbenzoate (NSC 615985, UC84). Nomeir AA; McComish MF; Ferrala NF; Silveira D; Covey JM; Chadwick M J Pharm Biomed Anal; 1998 May; 17(1):27-38. PubMed ID: 9608423 [TBL] [Abstract][Full Text] [Related]
22. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Finlay GJ; Baguley BC Cancer Chemother Pharmacol; 2000; 45(5):417-22. PubMed ID: 10803926 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM Cancer Chemother Pharmacol; 2001 Apr; 47(4):319-26. PubMed ID: 11345648 [TBL] [Abstract][Full Text] [Related]
24. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro). Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609 [TBL] [Abstract][Full Text] [Related]
25. Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity. Paxton JW; Jurlina JL Pharmacology; 1985; 31(1):50-6. PubMed ID: 3839584 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. Cornford EM; Young D; Paxton JW Cancer Chemother Pharmacol; 1992; 29(6):439-44. PubMed ID: 1568286 [TBL] [Abstract][Full Text] [Related]
28. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine. Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499 [TBL] [Abstract][Full Text] [Related]
29. Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. Evans SM; Robertson IG; Paxton JW J Pharm Pharmacol; 1994 Jan; 46(1):63-7. PubMed ID: 8201529 [TBL] [Abstract][Full Text] [Related]
30. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma. Baguley BC; Finlay GJ J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911 [TBL] [Abstract][Full Text] [Related]
31. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Schneider E; Darkin SJ; Lawson PA; Ching LM; Ralph RK; Baguley BC Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1783-90. PubMed ID: 2850193 [TBL] [Abstract][Full Text] [Related]
32. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986). Spiegel JF; Egorin MJ; Collins JM; Lerner BD; Bachur NR Drug Metab Dispos; 1983; 11(1):41-6. PubMed ID: 6132794 [TBL] [Abstract][Full Text] [Related]
33. Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase. Kettle AJ; Robertson IG; Palmer BD; Anderson RF; Patel KB; Winterbourn CC Biochem Pharmacol; 1992 Nov; 44(9):1731-8. PubMed ID: 1333205 [TBL] [Abstract][Full Text] [Related]
34. Highly sensitive analysis of the anti-tumor agent 1-[4-(furo[2,3-b]-quinolin-4-ylamino)phenyl]ethanone in rat plasma by high-performance liquid chromatography using electrochemical detection. Huang YB; Wu PC; Hsu MW; Chen YL; Tzeng CC; Tsai YH J Pharm Biomed Anal; 2005 Jul; 38(3):551-5. PubMed ID: 15925259 [TBL] [Abstract][Full Text] [Related]
35. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. McKeage MJ; Kestell P; Denny WA; Baguley BC Cancer Chemother Pharmacol; 1991; 28(6):409-13. PubMed ID: 1934244 [TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal administration of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Evans SM; Young D; Robertson IG; Paxton JW Cancer Chemother Pharmacol; 1992; 31(1):32-6. PubMed ID: 1458557 [TBL] [Abstract][Full Text] [Related]
37. Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Paxton JW; Young D; Evans SM; Robertson IG; Kestell P Cancer Chemother Pharmacol; 1993; 32(4):320-2. PubMed ID: 8324875 [TBL] [Abstract][Full Text] [Related]
38. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830 [TBL] [Abstract][Full Text] [Related]
39. Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination. Kestell P; Rewcastle GW; Baguley BC Xenobiotica; 1994 Jul; 24(7):635-47. PubMed ID: 7975728 [TBL] [Abstract][Full Text] [Related]
40. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. Harvey VJ; Hardy JR; Smith S; Grove W; Baguley BC Eur J Cancer; 1991; 27(12):1617-20. PubMed ID: 1664218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]